Reig Jofre Invests 5.8 Million in Leanbio and Increases Stake to 24%

Reig Jofre continues its expansion policy. The Catalan pharmaceutical company has announced an investment of 5.8 million euros in the biotechnology company Leanbio , with the aim of vertical integration in the development, characterization and production of biotechnology-based active ingredients.

To date, Reig Jofre participates in 10% of Leanbio’s capital. The operation, articulated through capital and debt, has been led by the pharmacy together with other Leanbio partners. As a result, Reig Jofre will increase its stake in Leanbio to 24% , committing to continue increasing its presence as the expansion plan progresses.

This investment will allow the companies to offer integrated services throughout the chain from development stages to industrial scale-up for the commercialization of recombinant proteins, antibodies and advanced therapies both for the multinationals with which they already collaborate, which require the specialized knowledge of both. partners , as well as for the start-up ecosystem in Spain and Europe.

This includes everything from the development and production of the biological active ingredient to the finished pharmaceutical product at the Reig Jofre facilities in Barcelona.

At the same time, this collaboration will allow Leanbio, which until now had facilities for the characterization, development, scaling and production of biotechnological products up to the preclinical phase, to advance in its expansion project and capitalize on its know-how and experience, reinforcing its facilities through the development of a new GMP (Good Manufacturing Practices) certified plant to produce biotechnology-based active ingredients and mRNA on an industrial scale.

Read more on the subject and find the most important financial news of the day with our companion app Born2Invest.

Reig Jofre will open a new 4,000 square meter plant

The plant located in Sant Quirze del Vallès (Barcelona) will occupy an area of ​​nearly 4,000 square meters. It will have three production lines with the capacity to manufacture recombinant proteins, antibodies in different expression systems, plasmid DNA and messenger RNA for advanced therapies within the biopharmaceutical sector, adapting to various production volumes.

Likewise, the plant will have development laboratories, scaling areas, pilot production plants and quality control.

In addition, the company anticipates that job creation will be gradual, with highly qualified personnel and that the team will exceed one hundred people when the plant reaches its maximum performance in 2030 . The plant is estimated to be operational in mid-2025.

This investment, they say, “marks significant progress” in the strategic collaboration between Reig Jofre and Leanbio, which began in 2018 with the creation of the joint venture Syna Therapeutics, in which they have a 50% stake for the development of biopharmaceutical products in the field of biosimilars and innovative molecules. In 2023, Syna Therapeutics announced the licensing of its first biosimilar to Accord Healthcare and continues to move forward on schedule.

“It is a great milestone for Reig Jofre, during its ninety years we have maintained specialization in the injectable pharmaceutical finished product, and now, together with Leanbio, we embark on the production of biotechnological active ingredients, taking advantage of the growing demand for new therapies. advanced post-Covid, such as cellular, gene and RNA therapies, which increasingly require services with specific scientific and technological know-how and specialized equipment and facilities to accompany this new era in which we are entering in the field of pharmacological therapies,” highlighted the CEO of Reig Jofre, Ignasi Biosca.

__

(Featured image by Nick Fewings via Unsplash)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce. A third-party contributor translated and adapted the articles from the originals. In case of discrepancy, the originals will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us